Glutamine cut IBS-D symptoms 14-fold over placebo in a randomized trial

If your digestive symptoms started right after a stomach bug and never fully went away, you are not imagining a connection. A specific subset of irritable bowel syndrome with diarrhea (IBS-D) begins this way, and researchers have long suspected it involves a "leaky gut," a gastrointestinal lining that lets more than it should slip through. A new randomized, double-blind, placebo-controlled trial published in the journal Gut tested a simple, low-cost intervention for exactly this group, and the results were large enough to be worth understanding in detail, caveats included.

Key takeaways

• In a controlled trial of patients with post-infectious IBS-D and confirmed intestinal hyperpermeability, 79.6% of patients on oral glutamine hit the study's symptom-relief target, versus 5.8% on placebo, a 14-fold difference.
• Glutamine also normalized the leaky-gut marker itself (intestinal permeability), stool frequency, and stool consistency, all with high statistical confidence.
• This is one trial in a narrowly defined patient group (post-infectious IBS-D with a confirmed permeability problem), not a green light for glutamine in IBS generally, and it has not yet been independently replicated.

Oral glutamine sharply reduced IBS-D symptoms in a controlled trial

Researchers at The Ohio State University Medical Center and the University of Texas Medical Branch ran an 8-week trial giving patients either oral glutamine or a placebo powder, then measured symptom relief using a validated tool called the Irritable Bowel Syndrome Severity Scoring System (IBS-SS, a standard questionnaire that scores abdominal pain, bloating, and bowel habits). The trial's primary target was a drop of at least 50 points on that scale, the threshold the field treats as a clinically meaningful improvement. Among patients who completed the study, 43 of 54 (79.6%) in the glutamine group hit that target, compared with just 3 of 52 (5.8%) in the placebo group. That gap, a roughly 14-fold difference, was highly statistically significant (p<0.0001), and 96% of the glutamine group showed at least some symptom improvement, with only two patients (3.7%) failing to respond at all.

Post-infectious IBS-D patients with leaky gut are the ones affected

This trial did not enroll people with IBS in general. Every participant had a specific history: diarrhea-predominant IBS (IBS-D) that developed after a documented gut infection, a pattern doctors call post-infectious IBS. On top of that, every enrolled patient had to test positive for intestinal hyperpermeability (elevated gut permeability, meaning the intestinal lining lets more molecules and bacterial byproducts pass into the bloodstream than it should), confirmed with a lactulose/mannitol urine test before randomization. IBS-D is common and often poorly served by existing drugs like rifaximin or eluxadoline, so a therapy that works specifically for the post-infectious, leaky-gut subgroup fills a real treatment gap for the roughly 106 people who make it through this kind of trial and for the wider population they represent.

A confirmed-permeability design gives the result more weight

What makes this study more convincing than a typical supplement claim is the design: it screened 287 candidates down to 115 randomized patients, all objectively confirmed to have both post-infectious IBS-D and elevated gut permeability before treatment began, rather than relying on symptoms alone. Fifty-nine were assigned to glutamine and 56 to placebo (a whey protein powder matched for color, texture, and taste), with 54 and 52, respectively, completing the full 8 weeks. Dosing was 5 grams of glutamine powder three times a day (15 grams total daily). Neither patients nor investigators knew who received which powder until after the data were analyzed, the gold-standard setup for ruling out placebo effect and expectation bias.

What this could mean if you suspect leaky gut is behind your symptoms

If your IBS-D symptoms trace back to a bout of food poisoning or a stomach virus, and you have not seen relief from standard first-line treatments, this trial gives you a specific, evidence-backed question to bring to a gastroenterologist: is intestinal permeability testing available, and would a supervised trial of oral glutamine make sense for you. The study's own authors describe the effect as large and consistent across multiple measures, not just the primary endpoint. Adverse events were rare and nearly identical between groups (3.8% in each arm), with no serious adverse events reported. That said, this is not a case for self-directed high-dose glutamine supplementation. The trial enrolled a narrowly defined, medically confirmed population, excluded pregnant or breastfeeding patients, children, and anyone with impaired liver or kidney function, and used a specific dose and duration under medical supervision.

One trial, one subgroup, and no independent confirmation yet

The authors themselves are direct about the limits here. This is the first randomized, controlled trial of its kind, meaning it has not yet been independently replicated by another research team, a step generally considered necessary before a finding becomes established medical guidance. It also only applies to the post-infectious IBS-D subgroup with confirmed hyperpermeability, not to IBS-D broadly and not to constipation-predominant IBS. The researchers also note that using whey protein as the placebo carries a small theoretical risk of its own gut effects, though they observed no symptom worsening in that group. Results in other populations, longer durations, or different doses remain unknown.

Larger trials are the next step researchers say are needed

The study authors explicitly call for larger randomized trials to confirm the finding, evaluate quality-of-life benefits more fully, and pin down the exact pharmacological mechanism. They also want future work to test a wider range of doses and longer treatment periods than the 8 weeks used here, since this trial cannot say whether the benefit holds up, fades, or needs maintenance dosing over time. Until that confirmatory work exists, this remains a single, well-designed but unreplicated study.

Common Questions

Is this the same as taking glutamine for general gut health? No. This trial tested a specific population (post-infectious IBS-D with lab-confirmed intestinal hyperpermeability) at a specific dose (15 grams a day) for 8 weeks under medical supervision. It does not establish that glutamine helps general digestive wellness or unconfirmed leaky gut symptoms.

How would someone know if they have intestinal hyperpermeability? In this study, it was confirmed with a lactulose/mannitol urine test administered by researchers, not a symptom checklist or an over-the-counter test. Ask a gastroenterologist whether permeability testing is appropriate and available for your situation.

Did the placebo group get worse? No. The placebo group (on whey protein powder) saw far less improvement than the glutamine group, but the trial did not report meaningful symptom worsening in that arm.

Why does glutamine plausibly help here? Glutamine is the primary fuel source for the rapidly dividing cells that line the gut. When it is depleted by infection or stress, those cells can weaken along with the tight junction proteins that hold the intestinal barrier together. The trial's data showed glutamine treatment tracked with normalized permeability alongside symptom improvement, consistent with that proposed mechanism, though the exact pathway is still being studied.

References

QiQi Zhou, Meghan L Verne, Jeremy Z Fields, et al. (2018). Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. https://doi.org/10.1136/gutjnl-2017-315136